Female children respond to recombinant hepatitis B vaccine with a higher titre than male

J Trop Pediatr. 1994 Apr;40(2):104-7. doi: 10.1093/tropej/40.2.104.


One-hundred and eighty Chinese children [age range 5 months to 12 years, seronegative for all hepatitis B virus (HBV) markers] of parents seropositive for HBV surface antigen (HBsAg) were randomized to receive doses of either 10 or 20 micrograms of recombinant yeast-derived HBV vaccine at intervals of 0, 1, and 6 months. Six children defaulted and three other children (1.7 per cent) seroconverted to anti-HBc positivity without detectable HBsAg in the serum. All other children attained an anti-HBs titre of > 10 mlU/ml after three doses. Both 10 and 20 micrograms/dose regime gave a similar geometric mean titre (GMT) of anti-HBs. Children aged 0-4 responded with a similar titre compared with children aged > 4. Female children responded with a significantly higher GMT than male children and this was due to a high proportion of female children with higher peak titres. No major side-effects were encountered. We conclude that recombinant HB vaccine is highly immunogenic, well tolerated and equally effective with doses of both 10 and 20 micrograms and that girls responded with a higher anti-HBs titre compared with boys.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Hepatitis B Vaccines / administration & dosage*
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Sex Factors
  • Vaccines, Synthetic / administration & dosage


  • Hepatitis B Vaccines
  • Vaccines, Synthetic